GSA Capital Partners LLP Purchases Shares of 483,768 Allogene Therapeutics, Inc. (NASDAQ:ALLO)

GSA Capital Partners LLP acquired a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 483,768 shares of the company's stock, valued at approximately $706,000. GSA Capital Partners LLP owned 0.22% of Allogene Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. American Century Companies Inc. grew its position in Allogene Therapeutics by 16.5% during the fourth quarter. American Century Companies Inc. now owns 232,356 shares of the company's stock valued at $495,000 after buying an additional 32,935 shares during the period. Sei Investments Co. acquired a new stake in shares of Allogene Therapeutics during the 4th quarter valued at about $103,000. KLP Kapitalforvaltning AS purchased a new position in shares of Allogene Therapeutics in the 4th quarter valued at about $43,000. PAX Financial Group LLC purchased a new position in shares of Allogene Therapeutics in the 4th quarter valued at about $27,000. Finally, Wells Fargo & Company MN raised its holdings in Allogene Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 104,593 shares of the company's stock worth $223,000 after purchasing an additional 23,779 shares during the period. 83.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on ALLO shares. Royal Bank Of Canada reissued an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Robert W. Baird dropped their price target on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. Oppenheimer cut their price target on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. Piper Sandler decreased their price objective on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Finally, Citizens Jmp lowered shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 14th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Allogene Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.44.

Allogene Therapeutics Stock Down 12.2%

Shares of NASDAQ ALLO opened at $1.08 on Friday. The firm has a 50-day simple moving average of $1.28 and a 200-day simple moving average of $1.51. The stock has a market capitalization of $236.23 million, a price-to-earnings ratio of -0.88 and a beta of 0.35. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). As a group, equities research analysts expect that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.